Table 3.
Predicted resistance level and INSTI mutations identified in INSTI-naïve patients.
| Mutations | Genetic form | INSTI resistance level† | ||||||
|---|---|---|---|---|---|---|---|---|
| Major | Accessory | All (n = 25) |
B n = 14) |
Non-B (n = 11) | RAL | EVG | DTG | BIC |
| G163R | 11‡ | 5‡ | 6‡ | Low | Low | Susceptible | Susceptible | |
| G163K | 6 | 3 | 3‡ | Low | Low | Susceptible | Susceptible | |
| E138K | 4‡ | 2‡ | 2‡ | Low | Low | Susceptible | Susceptible | |
| S230R | 1 | 1 | Low | Low | Low | Low | ||
| E92G | 1‡ | 1‡ | Low | Intermediate | Susceptible | Susceptible | ||
| V151A | 1 | 1 | Low | Intermediate | Susceptible | Susceptible | ||
| N155H | T97A | 1 | 1 | High | High | Susceptible | Susceptible | |
†RAL: Raltegravir, EVG: Elvitegravir, DTG: Dolutegravir, BIC: Bictegravir.‡Newly-diagnosed patients: G163R was found in 3 NDs (1 subtype B and 2 non-subtype B). E138K was found in 2 ND (1 subtype B and 2 non-subtype B).